Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer

Background: Lifetime cumulative doses of conventional doxorubicin (>450 mg/m2) are associated with dose-dependent cardiotoxicity. In sarcoma and breast cancer, conventional doxorubicin is often utilized in the adjuvant setting, whereas pegylated liposomal doxorubicin (PLD) is typically reserved f...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhaja, Maher, Chen, Sherry, Chin, Alan C, Schulte, Brian, Legasto, Carlo S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559758/
https://www.ncbi.nlm.nih.gov/pubmed/37809186
http://dx.doi.org/10.7759/cureus.44837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559758/
https://www.ncbi.nlm.nih.gov/pubmed/37809186
http://dx.doi.org/10.7759/cureus.44837

Ejemplares similares